Literature DB >> 31575423

Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.

Timothy B Plante1, Stephen P Juraschek2, Neil A Zakai3, Russell P Tracy4, Mary Cushman3.   

Abstract

The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary prevention populations is unknown. We sought to compare ASCVD events by level of PCE-predicted risk among primary and secondary prevention SPRINT populations. SPRINT randomized adults with hypertension and ≥1 CVD risk factor or previous CVD events to systolic blood pressure control targeting <120 mm Hg or 135 to 139 mm Hg. We calculated the hazard ratio (HR) of ASCVD events among secondary versus primary (reference) prevention subgroups overall and by predicted 10-year ASCVD risk categories (<10%, 10% to <20%, 20% to <30%, and ≥30%) and within risk subgroups, comparing to the lowest risk category. Among 8,151 participants, 16% with previous CVD, mean age was 66 years and 35% were women. The HR for ASCVD events overall was 2.51 (1.96, 3.20). HR was 2.97 (1.47, 5.99) among <10% 10-year risk and 2.23 (1.38, 3.59) among ≥30% risk. Within subgroups comparing ≥30% to <10% risk (reference) categories, the HR was 2.85 (1.76, 4.63) for primary and 2.14 (1.07, 4.30) for the secondary prevention. In conclusion, history of previous events was a potent risk factor for subsequent ASCVD events. The PCE does not enhance risk prediction among secondary prevention populations and may differentially underestimate risk in secondary prevention populations with lowest predicted risk.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31575423      PMCID: PMC7240131          DOI: 10.1016/j.amjcard.2019.08.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.

Authors:  Paul Muntner; Lisandro D Colantonio; Mary Cushman; David C Goff; George Howard; Virginia J Howard; Brett Kissela; Emily B Levitan; Donald M Lloyd-Jones; Monika M Safford
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

3.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

4.  Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events With Systolic Blood Pressure <120mm Hg Versus 135-139mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup.

Authors:  Timothy B Plante; Stephen P Juraschek; Edgar R Miller; Lawrence J Appel; Mary Cushman; Benjamin Littenberg
Journal:  Am J Cardiol       Date:  2018-07-04       Impact factor: 2.778

5.  Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension.

Authors:  Robert A Phillips; Jiaqiong Xu; Leif E Peterson; Ryan M Arnold; Joseph A Diamond; Adam E Schussheim
Journal:  J Am Coll Cardiol       Date:  2018-03-07       Impact factor: 24.094

Review 6.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

7.  Utility of the Framingham Risk Score in predicting secondary events in patients following percutaneous coronary intervention: A time-trend analysis.

Authors:  Jaskanwal D S Sara; Ryan J Lennon; Rajiv Gulati; Mandeep Singh; David R Holmes; Lilach O Lerman; Amir Lerman
Journal:  Am Heart J       Date:  2015-11-14       Impact factor: 4.749

8.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

9.  Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.

Authors:  Johannes A N Dorresteijn; Frank L J Visseren; Annemarie M J Wassink; Martijn J A Gondrie; Ewout W Steyerberg; Paul M Ridker; Nancy R Cook; Yolanda van der Graaf
Journal:  Heart       Date:  2013-04-10       Impact factor: 5.994

10.  A general cardiovascular risk profile: the Framingham Study.

Authors:  W B Kannel; D McGee; T Gordon
Journal:  Am J Cardiol       Date:  1976-07       Impact factor: 2.778

View more
  2 in total

1.  Evaluation of Persistent Efficacy of Diabetes Remission and Decline of Cardiovascular Risk After Laparoscopic Sleeve Gastrectomy: a Preliminary 1-Year Study.

Authors:  Yu-Min Huang; Weu Wang; Shu-Chen Wei; Pei-Fen Lee; Yi-Chiang Hsu; Wan-Ling Tu; Hsin-Hung Chen
Journal:  Obes Surg       Date:  2022-07-23       Impact factor: 3.479

2.  Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.

Authors:  Susanna R Stevens; Matthew W Segar; Ambarish Pandey; Yuliya Lokhnygina; Jennifer B Green; Darren K McGuire; Eberhard Standl; Eric D Peterson; Rury R Holman
Journal:  Cardiovasc Diabetol       Date:  2022-08-27       Impact factor: 8.949

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.